Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Beta Bionics

Tracked across 6 events · 143 articles · First seen Feb 04, 2026 · Last active Sep 22, 2026

Sentiment
-22
Attention
4
Events
6
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
3 -70
Business
Impact: Beta Bionics is facing a securities litigation investigation by Faruqi & Faruqi, LLP after its stock plunged 37% due to lower-than-expected patient starts in Q4.
Feb 04, 2026 · 6 articles
4 -70
Regulatory
Impact: Beta Bionics is facing investigations by multiple law firms for potential securities law violations and breach of fiduciary duties after its stock price declined significantly due to slower new patient start growth.
Jun 01, 2026 · 35 articles
2 -60
Regulatory
Multiple investor-rights law firms have filed federal securities class actions against Beta Bionics, Inc. (NASDAQ: BBNX) and certain of its officers on behalf of purchasers of Beta Bionics common stock between July 30, 2025 and…
Impact: Beta Bionics is the primary defendant in the securities class actions, facing allegations of false and misleading statements regarding its iLet Bionic Pancreas insulin pump and failure to disclose serious FDA findings. The litigation and underlying regulatory issues could materially harm its stock price, reputation, and business prospects.
Sep 05, 2026 · 68 articles
2 10
Business
Beta Bionics, Inc. (Nasdaq: BBNX), a commercial-stage medical device company focused on insulin delivery solutions for people with diabetes, completed an underwritten public offering of common stock. On September 15, 2026, Beta Bionics announced its…
Impact: Beta Bionics is the issuer and sole seller of the shares, raising $172.5 million in gross proceeds to fund commercialization of Mint, manufacturing expansion, and R&D. The offering strengthens its balance sheet but dilutes existing shareholders.
Sep 15, 2026 · 7 articles
4 60
Regulatory
Impact: Beta Bionics is collaborating with Abbott to integrate its iLet automated insulin delivery system with the Libre Duo sensor, expected by end of 2026. This partnership enhances its product ecosystem.
Aug 25, 2026 · 21 articles
2 0
Business
Apr 27, 2026 · 6 articles
90 Hagens Berman filed securities class action Beta BionicsBeta Bionics Securities...
85 Levi & Korsinsky filed securities class action Beta BionicsBeta Bionics Securities...
80 Beta Bionics made false statementsBeta Bionics Securities...
75 Beta Bionics concealed safety complaintsBeta Bionics Securities...
75 Beta Bionics disclosed Warning LetterBeta Bionics Securities...
72 Beta Bionics missed patient start estimatesBeta Bionics Securities...
70 Beta Bionics announced public offeringBeta Bionics $172.5M...
65 Beta Bionics failed corrective actionsBeta Bionics Securities...
30 JPMorgan Chase acted as book-running manager Beta BionicsBeta Bionics $172.5M...
+ 3 more actions View on Dashboard
ERGEN INTELLIGENCE
Track Beta Bionics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.